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Accepted 23 September 2010AbstractObjective: Simultaneous mifepristone 200 mg and vaginal misoprostol 800 mg produces a complete abortion rate of approximately 90% at up to
63 days of gestation. The aim of this study was to determine the effectiveness of concurrent administration of mifepristone 200 mg and vaginal
misoprostol 600 mg with respect to early medical abortion.
Materials and Methods: A total of 254 women with undesired pregnancies of less than 49 days of gestation were enrolled. All women received
oral mifepristone 200 mg and vaginal misoprostol 600 mg concurrently. Follow-up assessment by transvaginal ultrasonography was performed 3
days and 2 weeks after treatment.
Results: Efficacy outcome was analyzed for 242 women (95.3%) after excluding 12 individuals lost to follow-up. The complete abortion rate was
92.6%. The mean induction to abortion interval was about 5.8 hours. The mean bleeding duration was about 12.6 days. The women indicated
that the side effects were tolerable and 90% of them said that their experience was satisfactory.
Conclusion: Concurrent administration of oral mifepristone 200 mg and vaginal misoprostol 600 mg is an efficacious regimen for medical
abortion of pregnancies up to 49 days of gestation.
Copyright  2011, Taiwan Association of Obstetrics & Gynecology. Published by Elsevier Taiwan LLC. All rights reserved.
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Surgical treatment has been used as the method of choice
for early termination of pregnancy for many years, but
significant complications do occur, including uterine perfora-
tion, hemorrhage, and retained products of conception.
Recently, the medical management of pregnancy termination
has become more popular than surgical management. Medical
management with misoprostol is most frequent and is regu-
larly offered for the termination of pregnancy. Different doses* Corresponding author. Department of Obstetrics and Gynecology, Kuo
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doi:10.1016/j.tjog.2010.09.002of misoprostol for the termination of early pregnancy have
been reported.
The use of medical abortion to terminate early pregnancy has
evolved greatly. Clinical studies have demonstrated that oral
administration of mifepristone (RU 486) 600 mg, followed by
the oral use of misoprostol 400 mg 36e48 hours later, results in
a complete abortion rate of 87e96% at up to 49 days of
gestation [1e4]. Large randomized trials have proved that
regimens using a lower dose of mifepristone are equivalently
effective [5,6]. Furthermore, alternative means of administration
of misoprostol, including vaginal, buccal, and sublingual
approaches, have also been used at 49 days of gestation or less.
Research has shown that the vaginal administration of
misoprostol is characterized by a slow absorption but a longcs & Gynecology. Published by Elsevier Taiwan LLC. All rights reserved.
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metabolism by the liver. In these circumstances, the vaginal
bioavailability of misoprostol is three times greater than the
oral bioavailability [7]; thus, vaginal administration of miso-
prostol has a relatively higher success rate for abortion than
oral administration.
A recent study has shown that effectiveness remains the
same even if the interval between the administration of
mifepristone and the subsequent administration of misoprostol
is decreased from 36e48 hours to 6e8 hours [8]. Shortening
the interval between the administration of mifepristone and
misoprostol is scientifically plausible. Furthermore, research
has revealed that the therapeutic effect is also good even when
the two drugs are used concurrently.
In a previous report, we demonstrated a 97.8% abortion rate
by the concurrent administration of mifepristone 200 mg and
vaginal misoprostol 800 mg when used for early pregnancy
termination [9]. However, we envisaged in this study the use
of a lower dose of misoprostol in order to reduce any adverse
effects. Evidence suggests that any adverse effects associated
with early pregnancy terminations using mifepristone and
misoprostol, such as nausea, gastrointestinal complaints, and
pain from cramping, may be related to the dose of misoprostol
and the route by which it is administered [10]. Vaginal
administration of misoprostol 800 mg seems to have more
adverse effects in previously published reports [11e13];
therefore, this had led to investigate the efficacy of mifepris-
tone 200 mg and misoprostol 600 mg vaginally in order to
determine the effectiveness and its adverse events of this
procedure on early medical abortion. Given that low dose of
misoprostol is thought to be insufficient or effective uterine
contractions to produce high-abortion rate, we did not try
misoprostol 400 mg or 200 mg in this study.
Materials and methods
From November 2005 to October 2009, a total of the 254
women seeking elective termination of pregnancy were
progressively enrolled. All the consenting women who pre-
sented for abortion services met the following inclusion criteria:
(1) the patient requested a medical abortion; (2) an intrauterine
pregnancy up to 49 days gestational was confirmed using
vaginal ultrasonography and the ultrasound was also used to
exclude an ectopic pregnancy and to estimate gestational age;
(3) the patient had signed an consent agreement, had been
informed of the advantages/risks of medical abortion, and
understood the necessity of receiving a surgical abortion if the
medical abortion failed; and (4) the patient promised to attend
the follow-up appointments.
No medical abortions were performed on pregnant women
with any of the following exclusion criteria: (1) allergy to
mifepristone or prostaglandins; (2) the presence of symptoms
associated with threatened abortion; (3) a medical history of
heart, respiratory system, kidneys, liver, or adrenal disease; (4)
a medical history of thromboembolism, hypertension, coa-
gulopathy, glaucoma, or diabetes mellitus; (5) a medical
history of uterine pathology; (6) a hemoglobin level of lessthan 10 g/dL; (7) a pregnancy involving an intrauterine device
in utero; or (8) the presence of an active pelvic infection.
To induce abortion, the women received 200 mg of oral
mifepristone followed by the immediate intravaginal placement
of 600 mgmisoprostol. To relieve symptoms due tomisoprostol,
subjects were given a prescription for three tablets of 500 mg
acetaminophen for the treatment of abdominal pain if they
needed it. Participants returned 3 days after administration of
the combination. After being questioned regarding side effects,
a vaginal ultrasound was performed. The side effects involved
were pelvic pain, shivering (generalized tremor 30 seconds),
fever (37.5 C), nausea, vomiting, diarrhea, and dizziness. All
participants were scheduled for a second follow-up visit at Day
14 after the procedure. At the follow-up visits, each woman’s
abortion and clinical status were assessed again. A result was
considered to be a complete abortion when the transvaginal
sonography demonstrated a regular smooth endometrial cavity.
Women with retained products in the uterus were offered the
option of waiting an additional week to see if these products
would evacuate on their own. Suction curettage was also per-
formed at any time if it was clinically necessary because of
uterine hemorrhage, incomplete abortion, or at the subject’s
request.
Complete medical abortion without surgical intervention
was classified as treatment success. All outcomes that resulted
in a surgical intervention were classified as treatment failure. At
each of the participant’s final follow-up visit, she completed
a visual analog scale (VAS) measuring the amount of pain
experienced during the abortion process. On a 100-mm line, “0”
represent no pain and “100” represented severe pain. In addi-
tion, at the same time, the patients filled out a questionnaire
designed to determine whether they agreed that the medical
abortion was performed to their satisfaction. The questionnaire
consisted of multiple-choice questions with the following
choices: strongly disagree; disagree; neutral; agree; strongly
agree. This study was approved by the Institutional Review
Board and written informed consent was obtained from all
participants.
Results
Of the 254 enrolled patients, 12 were lost to follow-up and
were not included in analysis; as a result, 242 participants
completed this study. The mean age of the 242 women was
about 25.2 years (range, 18e46 years), and themean gestational
age was about 45.2 days (range, 36e49 days). When parity was
analyzed, 140 (57.9%) women were nulliparous, 38 (15.7%)
were primiparous, and 64 (26.4%) were multiparous. The mean
time from drug administration to bleeding was about 3.2 hours
(range, 1.2e6.5 hours), and the mean time to expulsion of the
products of the pregnancy was about 5.8 hours (range,
3.2e10 hours). The mean duration of self-assessed bleeding
days was about 12.6 days (range, 9e32 days).
The efficacy outcome was analyzed for the 242 women.
Overall, 224 (92.6%) of the participants underwent complete
abortion after completion of the treatment regimen. In the end,
18 (7.4%) women opted for dilatation and curettage, including
Table 1
Number and percentage of side effects (n¼ 242)
Side effects n (%) Remarkable
Pelvic pain 174 (71.9) Mean VAS 48 (10e88) mm
Nausea 77 (31.8) Mean 3.6 (1e8) episodes
Fever 67 (27.7) Mild, 3 patients 38 C
Shivering 60 (24.8) Mean 3 (1e20) min
Vomiting 36 (14.9) Mean 2.2 (1e6) episodes
Headache 26 (10.8) Mild
Diarrhea 24 (9.9) Mild
Dizziness 19 (7.9) Mild
VAS¼ visual analog scale.
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medical indications (incomplete abortion and hemorrhage),
and two (0.8%) due to patient request. All the histopatholog-
ical findings of the curettage specimens revealed the presence
of retained products of conception without involvement of
malignancy.
Adverse effects included abdominal pain in 174 (71.9%)
women, nausea in 77 (31.8%), fever in 67 (27.7%), shivering in
60 (24.8%), vomiting in 36 (14.9%), headache in 26 (10.7%),
diarrhea in 24 (9.9%), dizziness in 19 (7.9%), and the symptoms
were mostly mild to moderate with the participants not
requiring any medication except analgesia. The mean level of
pain reported via the post-questionnaire was 48 mm (range,
10e80 mm). The mean number of episodes of vomiting was 2.2
(range, 1e6 episodes). Hemorrhage and pelvic infection were
rare after treatment. No patient was found to have endometritis
and only three (1.2%) patients had a temperature of 38.0 C or
greater but this was without any infectious sign. Two (0.8%)
patients required some uterotonic medication (ergometrine) due
to excessive vaginal bleeding and no one needed a blood
transfusion. Table 1 provides details of the women’s reports of
the adverse effects experienced following vaginal misoprostol
administration. Regarding how much patients agreed that the
therapy they had received was performed to their satisfaction,
the following answers were received: strongly agree by 181
women (75%), agree by 37 women (15%), neutral by 18 women
(7%), disagree by 6women (3%); which gives a satisfaction rate
of 90% (218/242).
Discussion
To achieve a medical abortion, patients typically take
misoprostol 36e48 hours after taking mifepristone. Clinical
trials are currently underway to investigate variations in the
dose, timing, and route of misoprostol when it is used in
conjunction with mifepristone, the aim being to simplify
follow-up procedures so that they are more convenient for theTable 2
Comparison of the side effects of clinical trials of mifepristone and vaginal misop
Authors Dose of misoprostol (mg) Cramping (%) Nausea (%) Fe
Murthy et al [11] 800 100 60 55
Schreiber et al [12] 800 100 63 53
Creinin et al [13] 800 97 58 69
Present study 600 71.9 31.8 27patient [4e6,14]. No previous studies have tested a 600 mg
dose of vaginal misoprostol and 200 mg of oral mifepristone
simultaneously in the first trimester. The result of our study
indicated that when 600 mg misoprostol was administered
vaginally concurrent with mifepristone, a 92.6% success rate
for complete abortion at up to 49 days’ gestation was
demonstrated. The efficacy and adverse effects are consistent
with those previously reported using other medical abortion
protocols, and the approach achieved a high satisfaction rate of
90%. There was no need to hospitalize any individual because
of the presence of hemorrhage or endometritis.
We used vaginal misoprostol in our study based on what we
have learned from other medical abortion studies. When used in
regimens for medical abortion after mifepristone treatment,
vaginal misoprostol results in a higher rate of complete abortion
than oral misoprostol, as well a more rapid rate of pregnancy
expulsion [1]. The simultaneous use of mifepristone and
misoprostol is able to shorten the amount of time necessary for
a medical abortion, and has the potential to reduce patient
anxiety. To the best of our knowledge, this protocol has not been
attempted or reported before.
In 2005, Murthy and associates [11] reported that, in 40
women with pregnancies less than 7 gestational weeks who
received oral mifepristone 200 mg and concurrent vaginal
administration of misoprostol 800 mg, a complete abortion rate
of 98% was achieved after 2 weeks, with only one woman
requiring suction and curettage because of an incomplete
abortion. Their conclusion was that the combined administra-
tion of mifepristone and misoprostol to pregnant women less
than 7 gestational weeks is an efficacious way of achieving
medical abortion.
Similarly, Schreiber and colleagues [12] tested 40 pregnant
women in a 50e56 days’ gestation (Group 1) and 40 pregnant
women in a 57e63 days’ gestation (Group 2) using oral mife-
pristone 200 mg and immediate vaginal administration of
misoprostol 800 mg; these individuals underwent vaginal
ultrasonography 24 hours and 2 weeks afterwards. They found
that by the second week, the complete abortion success rates
were 93% and 90% in Groups 1 and 2, respectively. They
concluded that mifepristone and misoprostol are efficacious in
women with pregnancies of 8e9 gestational weeks, whether
administered concurrently or one after the other 36e48 hours
later. However, these results are slightly unsatisfactory because,
compared to the study of Murthy et al, Schreiber et al’s study
involved pregnant women at 50e56 days’ gestation (8 weeks)
and 57e63 days’ gestation (9 weeks), compared to<49 days of
gestation in Murthy et al’s study.
In same way, Creinin and colleagues [13] minimized the
dosing interval by simultaneously administering mifepristonerostol administered simultaneously for abortion
ver/chills (%) Dizziness (%) Vomiting (%) Headache (%) Diarrhea (%)
53 25 18 e
e 40 e 40
39 31 40 35
.7 7.9 14.9 10.7 9.9
Table 3
Comparison of the clinical trials of mifepristone and vaginal misoprostol administered simultaneously for abortion
Authors Patient number Gestational day Mifepristone
dose (mg)
Misoprostol dose (mg) Mean VAS score Success rate (%)
Murthy et al [11] 40 49 200 800 5.7 98
Schreiber et al [12] 40 50e56 200 800 6.3 93
Schreiber et al [12] 40 57e63 200 800 6.1 90
Creinin et al [13] 554 63 200 800 6.4 95.1
Present study 254 49 200 600 4.8 95.3
VAS¼ visual analog scale.
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1,128 participants with an intrauterine pregnancy at 63 days of
gestation ingested mifepristone 200 mg and then the subjects
were randomized into groups. The first group was treated
vaginally with misoprostol 800 mg immediately and the other
group was treated orally withmisoprostol 800 mg 24 hours later.
They found this regimen to be as effective when compared to
regimens using a 24-hour dosing interval; the complete abortion
rates were 95.1% versus 96.9%, respectively. However, the
benefit of mifepristone added to 800 mg of vaginal misoprostol
when dosed in concert can be questioned because the high-
abortion efficacy may potentially be solely due to the high-
misoprostol dose.
In another study reported by Lohr et al [15], a pilot trial was
performed with the primary objective of evaluating 24-hour
expulsion rate after simultaneous administration of mifepris-
tone 200 mg and buccal misoprostol 800 mg. This trial
involved 120 women, with 40 women in each of the gesta-
tional age ranges of 49 days or less, 50e56 days, and 57e63
days of gestation. The expulsion rates were 73%, 69%, and
73% respectively. However, the women achieved relatively
high-complete abortion rates at 2 weeks of 97.5%, 100%, and
94.9% respectively.
It should be noted that women who want to avoid surgery
seem to value the option of a medical abortion and tend to be
satisfied regardless of the regimen used. This was also true in
our study in which 90% of subjects were satisfied with our
method. In addition, the administration of misoprostol 600 mg
vaginally in this study appears a trend of less frequently in all
side effects without interfering with the efficacy of medical
abortion for early pregnancy. The comparison of side effects of
this study with previously published reports of administering
oral mifepristone 200 mg and 800 mg misoprostol vaginally
for medical abortion concurrently is listed in Table 2. And the
comparison of baseline characteristics, methods and efficacy
outcome of these reports are listed in Table 3.
The ultimate goal of our research is to improve the technique
used for termination of early pregnancy. Guidelines for mife-
pristone medical abortion in the USA have widely recom-
mended vaginal misoprostol based on the view that it is more
effective and more acceptable [16]. Our hypothesis is that
vaginal 600 mg will be sufficient and that a dose of 800 mg is not
needed. In fact, if the lower dose has a similar efficacy, it would
be unethical to continue using a dose that is unnecessarily high
because this is likely to cause more side effects and increase the
costs of the treatment [10]. Based on our results, simultaneous
200 mg mifepristone and 600 mg misoprostol vaginally, givenits simplicity, and ease of administration, is recommended for
further study as a treatment for medical abortion.References
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